*Correspondence: Juan Pablo Del Ro, [email protected] This article was submitted to Neuroendocrine Science, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
- La semaglutida oral es eficaz, segura y bien tolerada en pacientes con DM2, incluso en aquellos con ERD, con los beneficios propios de esta familia de frmacos, lo que puede facilitar la introduccin ms precoz de un arGLP-1 en el manejo de la DM2
Reducing the release of glucose from the liver, which can help to lower blood sugar levels
Eighty-nine patients were previously included in the study by Le Guellec et al
Only one prospective study evaluated the impact of liraglutide versus placebo in 30 people with obesity and COPD at different times on lung function tests, 6 min walk test, and responses to a questionnaire on the clinical impact of COPD (COPD assessment testCAT score)